JP2022537581A5 - - Google Patents

Info

Publication number
JP2022537581A5
JP2022537581A5 JP2021576065A JP2021576065A JP2022537581A5 JP 2022537581 A5 JP2022537581 A5 JP 2022537581A5 JP 2021576065 A JP2021576065 A JP 2021576065A JP 2021576065 A JP2021576065 A JP 2021576065A JP 2022537581 A5 JP2022537581 A5 JP 2022537581A5
Authority
JP
Japan
Prior art keywords
patient
nucleoside
nucleic acid
oligonucleotide
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021576065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038703 external-priority patent/WO2020257631A2/en
Publication of JP2022537581A publication Critical patent/JP2022537581A/ja
Publication of JP2022537581A5 publication Critical patent/JP2022537581A5/ja
Withdrawn legal-status Critical Current

Links

JP2021576065A 2019-06-21 2020-06-19 Ｐｐｍ１阻害剤およびその使用方法 Withdrawn JP2022537581A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962864988P 2019-06-21 2019-06-21
US62/864,988 2019-06-21
US201962871356P 2019-07-08 2019-07-08
US62/871,356 2019-07-08
PCT/US2020/038703 WO2020257631A2 (en) 2019-06-21 2020-06-19 Ppm1a inhibitors and methods of using same

Publications (2)

Publication Number Publication Date
JP2022537581A JP2022537581A (ja) 2022-08-26
JP2022537581A5 true JP2022537581A5 (enExample) 2023-06-26

Family

ID=74040507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576065A Withdrawn JP2022537581A (ja) 2019-06-21 2020-06-19 Ｐｐｍ１阻害剤およびその使用方法

Country Status (9)

Country Link
US (1) US20220372489A1 (enExample)
EP (1) EP3987030A4 (enExample)
JP (1) JP2022537581A (enExample)
KR (1) KR20220035137A (enExample)
CN (1) CN114729355A (enExample)
AU (1) AU2020296104A1 (enExample)
CA (1) CA3144063A1 (enExample)
IL (1) IL289127A (enExample)
WO (1) WO2020257631A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024534157A (ja) * 2021-08-27 2024-09-18 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｓｃｎ１ａ発現を調節するための化合物及び方法
EP4441224A4 (en) * 2021-12-03 2026-03-11 Quralis Corp Antisense oligonucleotides with modified skeletal chemicals
KR102856378B1 (ko) * 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
KR102775989B1 (ko) * 2022-11-01 2025-03-04 윤주호 콜치신과 메트포르민을 유효성분으로 하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099611A1 (en) * 1995-09-01 2003-05-29 Sara Lavi Manipulation and detection of protein phosphatase 2c-pp2calpha - expression in tumor cells for cancer therapy, prevention and detection
KR19990044317A (ko) * 1995-09-01 1999-06-25 라미 핀클러 ; 하나넬 크바탄스키 아밀포스파타제2Ｃ - ＰＰ 2Ｃα-발현의 조작 및 검출
US20030050270A1 (en) * 1998-11-20 2003-03-13 Monia Brett P. Antisense modulation of Inhibitor-kappa B Kinase-beta expression
EP1423103A4 (en) * 2001-08-10 2008-03-19 Univ Rockefeller COMPOSITIONS AND METHOD FOR MODULATING DARPP-32 PHOSPHORYLATION
GB0207251D0 (en) * 2002-03-27 2002-05-08 Isis Innovation Lymphoma-associated antigens
US20040102397A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of PPM1B expression
JP2006500066A (ja) * 2002-09-25 2006-01-05 ファルマシア・コーポレーション ミクロソームのプロスタグランジンｅ２シンターゼ発現のアンチセンス調節
WO2004031377A1 (en) * 2002-10-04 2004-04-15 Bayer Healthcare Ag Regulation of human pp2c-like protein phosphatase
WO2011073903A1 (en) * 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers
AU2013374345A1 (en) * 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US11096956B2 (en) * 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof

Similar Documents

Publication Publication Date Title
JP2022537581A5 (enExample)
JP6175236B2 (ja) フィラグリン（ｆｌｇ）の発現および活性の調整によるｆｌｇ関連疾患の処置
JP2022536085A5 (enExample)
US20160201064A1 (en) Compositions and methods for modulating expression of frataxin
CA3142526A1 (en) Oligonucleotides and methods of use for treating neurological diseases
TW201923082A (zh) 用於降低snca表現之化合物及方法
JP2016530882A (ja) 筋強直性ジストロフィープロテインキナーゼ（ｄｍｐｋ）の発現を調節するための化合物及び方法
EP3765476B1 (en) Modified oligonucleotides for use in treatment of tauopathies
JP2022537581A (ja) Ｐｐｍ１阻害剤およびその使用方法
TW202111123A (zh) 用於減少fus 表現之化合物及方法
CN117642505A (zh) 靶向腺苷激酶的反义寡核苷酸
JP7788561B2 (ja) アンチセンスオリゴヌクレオチド及びその使用
AU2018421460B2 (en) Therapeutic uses and methods
CN119452086A (zh) 具有修饰的主链化学的gapmer反义寡核苷酸
WO2024249791A2 (en) Modified unc13a oligonucleotides
JP2025501682A5 (enExample)
EP3923937A1 (en) Combinations with thiazolidinediones for use in the prevention or treatment of abnormal bone growth
HK40121931A (zh) 具有修饰的主链化学的gapmer反义寡核苷酸
TW201828952A (zh) 調節血管舒緩素b1(klkb1)用於治療頭痛
EA053024B1 (ru) Антисмысловые олигонуклеотиды-переключатели сплайсинга с модифицированной химией скелета
HK40097883A (zh) 使用基因转录物调控剂治疗神经学疾病